超肥胖患者的跨导管大动脉植入:定义一个高风险的表型
Abdul Rasheed Bahar1, Waqas Ullah2, Yasemin Bahar1
1Detroit Medical Center/ Wayne State University, Detroit, MI, USA.
Critical pathways in cardiology
|December 30, 2025
概括
接受过导管大动脉植入术 (TAVI) 的超肥胖患者面临更高的早期死亡率和急性损伤等并发症的风险. 虽然仍存在一些风险,但长期的结果与BMI较低的患者相比较.
科学领域:
- 心血管医学 心血管医学
- 干预心脏病学 干预心脏病学
- 肥胖医学 肥胖医学
背景情况:
- 超肥胖症 (BMI ≥50 kg/m2) 对过导管大动脉植入 (TAVI) 结果的影响尚不清楚.
- 了解与极度肥胖相关的风险对于TAVI程序中的患者选择和管理至关重要.
研究的目的:
- 评估超级肥胖症与TAVI后的结果之间的关联.
- 为了比较超肥胖与非超肥胖的TAVI患者的短期和长期不良事件.
主要方法:
- 对TAVI程序的2015-2020年全国再接收数据库的分析.
- 超肥胖 (BMI ≥50 kg/m2) 和非超肥胖 (BMI <50 kg/m2) 患者的比较,使用倾向性得分匹配.
- 评估心血管不良事件 (NACE),死亡率和并发症在指数入院时的净不良事件,30日和180天.
主要成果:
- 超肥胖与NACE,住院死亡率和指数入院期间急性损伤的概率增加有关.
- 在30天后,只有超肥胖患者的急性损伤仍然明显高.
- 在180天后,永久心脏起器植入是超肥胖组中唯一显著增加的并发症.
结论:
- 超肥胖的TAVI接受者表现出更高的早期风险概况和持续的特定并发症风险.
- 极度肥胖症确定了高风险的TAVI表型,尽管长期的结果与BMI较低的患者大致相似.
更多相关视频
相关概念视频
Drug Dosing: Obese Patients
195
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
195
Atherosclerosis III: Management
291
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
291
Obesity
1.1K
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.1K
Aortic Regurgitation III: Medical Management
366
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
366
Mitral Valve Prolapse II: Assessment and Management
368
IntroductionA range of clinical features characterizes Mitral Valve Prolapse (MVP), but it is important to note that many individuals with MVP are asymptomatic and may remain so throughout their lives. For those who do exhibit symptoms, the following are the key clinical features:Palpitations: This is a common symptom where individuals feel an irregular or rapid heartbeat. Palpitations in MVP are often due to arrhythmias such as premature ventricular contractions or supraventricular...
368
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
218
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
218


